{
    "clinical_study": {
        "@rank": "164690", 
        "acronym": "PRIORITI", 
        "arm_group": [
            {
                "arm_group_label": "Triptorelin, 11.25 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Triptorelin, powder and solvent for suspension (prolonged released form)"
            }, 
            {
                "arm_group_label": "Active surveillance", 
                "arm_group_type": "No Intervention", 
                "description": "Active surveillance after radical prostatectomy (RP)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the benefit of immediate hormonal treatment after\n      Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer. To\n      reach this target, the trial will compare a group of patients treated with triptorelin at 8\n      weeks after the surgery and for a duration of 9 months (3 injections) versus another group\n      (called \"active surveillance group\") who will be not receiving triptorelin. Both groups will\n      be followed every 3 months to monitor any sign of disease progression during a minimum of 36\n      months"
        }, 
        "brief_title": "A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This trial is a phase IV (in Russia and China) as approved indication is locally advanced or\n      metastatic prostate cancer in both countries."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histopathologically confirmed adenocarcinoma of the prostate\n\n          -  Radical Prostatectomy with curative intent performed no more than 8 weeks before\n             randomisation\n\n          -  High risk criteria of disease progression, defined as follows:\n\n        Gleason score \u22658 on prostatectomy specimen, and/or Pre RP PSA level \u226520 ng/mL, and/or\n        Primary tumour stage 3a (pT3a) (with any PSA level and any Gleason score)\n\n          -  Post-RP PSA levels \u22640.2 ng/mL at 6 weeks\n\n        Exclusion Criteria:\n\n          -  Evidence of lymph nodes or distant metastasis\n\n          -  Positive margins\n\n          -  Evidence of any other malignant disease, not treated with a curative intent\n\n          -  Had surgical castration"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "226", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753297", 
            "org_study_id": "A-38-52014-194"
        }, 
        "intervention": {
            "arm_group_label": "Triptorelin, 11.25 mg", 
            "description": "Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)", 
            "intervention_name": "Triptorelin 11.25 mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Triptorelin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shijingshan", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Site #156002"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "Site #156003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shanxi"
                    }, 
                    "name": "Site #156004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Site #156011"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Site #156007"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "Site #156008"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "Site # 156010"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Site #156005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Site #156009"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "Site #156001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "Site #156006"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barnaul", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ekaterinburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Site #643007"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Patrick Cabri, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "BRFS defined as period of time from randomisation to time of Biochemical Relapse (BR). BR is defined as increased prostate specific antigen (PSA) >0.2 ng/mL confirmed by a second measurement performed 4 to 6 weeks later", 
            "measure": "Biochemical Relapse-Free Survival (BRFS)", 
            "safety_issue": "No", 
            "time_frame": "Every 3 months, up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "EFS is defined as the period of time from randomisation to time of first diagnosed locoregional disease recurrence (positive biopsy and/or node involvement) or first metastases (bone or visceral) or death from any cause", 
                "measure": "Event-Free Survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 5 years"
            }, 
            {
                "description": "OS defined as the time between randomisation and death from any cause", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 5 years"
            }, 
            {
                "description": "Disease-specific mortality measured as the time between randomisation and death related to prostate cancer", 
                "measure": "Time to disease-specific mortality", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 5 years"
            }, 
            {
                "description": "PSADT defined as the time from the first documented PSA increase >0.2 ng/mL to the time of the first value more than twice that of the first increased value", 
                "measure": "PSA Doubling Time (PSADT)", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months, up to 5 years"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}